Quick Take
Pliant Therapeutics (PLRX) intends to raise $90 million from the sale of its common stock in an IPO, plus another $10 million in a concurrent private placement, according to an amended registration statement.
The company is developing treatments for fibrosis, cancer and other serious medical conditions.
PLRX has produced very promising trial results, is well capitalized, has a strong collaboration and investment partner in Novartis (NVS) and the IPO appears to be reasonably priced.
Company & Technology
South San Francisco-based Pliant was founded to advance a pipeline of